Shares of Evogene Ltd. (NASDAQ:EVGN) have been given an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Brokerages have set a one year consensus price target of $8.00 for the company and are expecting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also given Evogene an industry rank of 107 out of 265 based on the ratings given to related companies.

An institutional investor recently raised its position in Evogene stock. Vanguard Group Inc. raised its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 436,225 shares of the biotechnology company’s stock after buying an additional 17,391 shares during the quarter. Vanguard Group Inc. owned about 1.70% of Evogene worth $2,443,000 as of its most recent filing with the Securities & Exchange Commission. 30.94% of the stock is owned by institutional investors.

Evogene (EVGN) remained flat at $$3.71 during trading hours on Friday. 9,150 shares of the company’s stock traded hands, compared to its average volume of 36,030. Evogene has a 12 month low of $2.66 and a 12 month high of $5.84. The company has a market capitalization of $95.53, a P/E ratio of -4.47 and a beta of 0.55.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

Evogene Company Profile

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with's FREE daily email newsletter.